Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
1995-05-09
2004-02-17
Schwadron, Ronald B. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007100, C435S007920, C435S007950, C435S007200, C436S501000, C436S087000, C436S536000, C436S543000, C436S518000, C436S820000, C530S300000, C530S324000, C530S826000
Reexamination Certificate
active
06692907
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Technical Field of the Invention
This invention relates generally to the field of hepatitis C virus (HCV) and, more specifically, to the discovery of an immunologically important motif in the E2/NS1 region.
2. Brief Description of Related Art
Hepatitis C virus (HCV) has been identified as the major causative agent of post-transfusion non-A, non-B hepatitis (NANBH). Materials and methods for obtaining the viral genomic sequences are known. See, e.g., PCT Publ. Nos. WO89/04669, WO90/11089, and WO90/14436. For general information about HCV, see Houghton et al. (1991), Hepatology 14:381-388.
Molecular characterization of the HCV genome indicates that it is a RNA molecule of positive polarity containing approximately 9,500 nucleotices comprising a long translational open-reading frame (ORF) that could encode a large polypeptide of approximately 3000 amino acids (aa) beginning with the first in-frame methionine codon. A hypervariable domain located at the amino terminus of the putative envelope glycoprotein E2/NS1 (also called E2) has been located, see PCT Publ. No. WO93/016126; Weiner et al. (1991), Virology 180:842-48; Weiner et al (1992), Proc. Natl. Acad. Sci. USA 89:3468-72; Weiner et al. (1992), Vaccines 92:303-08, Cold Spring Harbor Laboratory.
As observed for other RNA viruses, there is a substantial fluidity of the HCV genome resulting from an error-prone replicase and the absence of repair mechanisms that operate during DNA replication. Even in a single infected individual, the HCV genome does not exist as a homogeneous species. Rather, it exists as a quasi-species distribution of closely related but nevertheless heterogeneous genomes. Martell et al. (1992), J. Virol. 66:3225-3229. In addition, the process of host selection and adaptation of a rapidly mutating genome has led to the evolution of many distinct (yet still fluid) HCV genotypes. At least four different HCV genotypes can be distinguished according to the actual degree of nucleotide and amino acid relatedness of full length sequences, and additional different genotypes have been identified based on partial sequences. Mori et al. (1992), Biochem. Biophys. Res. Commun. 183:334-342; Chan et al., (1992), J. Gen. Virol. 73:1131; Cha et al. (1992), Proc. Natl. Acad. Sci. USA 89:7144-7148.
SUMMARY OF THE INVENTION
The present invention is directed to novel vaccine strategies for the treatment of HCV infection and assays for the diagnosis of HCV.
The hypervariable region of E2/NS1 (E2HV) between about amino acid 384 to about amino acid 414 is a rapidly evolving region of HCV and appears to be under positive immune selection. The present invention relates to the existence within this subregion of a motif that is immunogenic and conserved with respect to the character of the amino acids. Although the E2HV amino acid sequences need not be identical within this motif, a definite pattern exists. In HCV1, as well as a number of other isolates, this motif is seen at about amino acids 401 to 407. The presence of this motif in an immunogenic polypeptide is detectable by antibody binding.
The discovery of this motif within the E2/NS1 hypervariable region allows for a strategy of producing materials, including polypeptides and antibodies that may be used for treatment of HCV, whether by direct or passive immunization. Additionally, diagnostic methods employing immunoassays or nucleic acid assays are included herein.
Thus, in one aspect of this invention, a method for passively immunizing an individual for treatment of hepatitis C virus (HCV) infection is provided, the method comprising administering to the individual an antibody composition comprising an antibody capable of binding to a motif comprising an amino acid sequence
aa1-aa2-aa3-aa4-aa5-aa6 (SEQ ID NO:1)
wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A. In a further embodiment, aa7 is present and attached to aa6; aa7 is A, P, or S.
In another aspect of this invention, an antibody capable of recognizing an antigenic determinant is provided, wherein the antigenic determinant comprises the amino acid sequence
aa1-aa2-aa3-aa4-aa5-aa6 (SEQ ID NO:1)
wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A. In a further embodiment, aa7 is present and attached to aa6; aa7 is A, P, or S.
In a further aspect of this invention, an immunogenic polypeptide is provided comprising a motif characterized by
aa1-aa2-aa3-aa4-aa5-aa6 (SEQ ID NO:1)
wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A, provided that the motif is not contained within a 31 amino acid sequence of a naturally-occuring E2HV domain of an HCV isolate known as of May 12, 1993. In a further embodiment, aa7 is present and attached to aa6; aa7 is A, P, or S.
In a still further aspect of this invention, a vaccine is provided comprising: (1) at least one immunogenic polypeptide comprising a motif characterized by
aa1-aa2-aa3-aa4-aa5-aa6 (SEQ ID NO:1)
wherein aa1 is S, G, A, D, K, R or T; aa2 is L, F, I, M or W; aa3 is F or L; aa4 is any amino acid; aa5 is any amino acid; and aa6 is G or A; and (2) a pharmaceutically acceptable carrier.
In yet another aspect of this invention, a method of treating an individual for HCV infection is provided, the method comprising administering to the individual the vaccine as described above.
In another aspect of this invention, an immunoassay method for detecting anti-hepatitis C virus (HCV) antibodies in biological samples provided, the method comprising: (a) incubating an antibody-containing biological sample suspected of containing anti-HCV antibodies with a probe antigen comprising an immunogenic polypeptide as described above to permit the formation of an antibody-antigen complex; and (b) detecting the antibody-antigen complex containing the probe antigen.
REFERENCES:
patent: 4341761 (1982-07-01), Ganfield et al.
patent: 4399121 (1983-08-01), Albarella et al.
patent: 4427783 (1984-01-01), Newman et al.
patent: 4444887 (1984-04-01), Hoffmann
patent: 4466917 (1984-08-01), Nussenzweig et al.
patent: 4472500 (1984-09-01), Milstein et al.
patent: 4491632 (1985-01-01), Wands et al.
patent: 4493890 (1985-01-01), Morris
patent: 4629783 (1986-12-01), Cosand
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5574132 (1996-11-01), Lacroix
patent: 0 116 201 (1984-08-01), None
patent: 0 120 551 (1984-10-01), None
patent: 0 164 556 (1985-12-01), None
patent: 0 259 149 (1988-03-01), None
patent: 0 360 088 (1990-03-01), None
patent: WO 89/04669 (1989-06-01), None
patent: 9011089 (1990-10-01), None
patent: WO 90/14436 (1990-11-01), None
patent: WO 90/14837 (1990-12-01), None
patent: WO 92/08734 (1992-05-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 93/16126 (1993-08-01), None
Seaver, Gen. Eng. News, vol. 14, pp. 10 and 21, 1994.*
Berzofsky et al., Chapter 8, from : “Fundamental Immunology, Second Ed.” Ed. W.E. Paul, Raven Press Ltd., 1989, pp. 176, 177, 201, 202.*
Weiner et al., Proc. Nat. Acad. Sci. USA, 89:3468-3472, 1992.*
Barrett, J.T.,Basic immunology and its medical application,Second Edition, 1980, 14-17.
Botarelli, P. et al., “T-Lymphocyte Response to Hepatitis C Virus in Different Clinical Courses of Infection”,Gastroenterology,1993, 104, 580-587.
Brennan, M. et al., “The foliclle cells are a major site of vitellogenin inDrosophila melanogaster”, Dev. Biol.,1982, 89, 225-236.
Broach, R., “Construction of High Copy Yeast Vectors Using 2-&mgr;m Circle Sequences,”Meth. Enz.,1983, 101, 307-325.
Cha et al., “At least five related, but distinct, hepatitis C viral genotypes exist,”Proc. Natl. Acad. Sci. USA,1992, 89, 7144-7148.
Chakrabarti et al., “Vaccinia Virus Expression Vector: Coex
Houghton Michael
Weiner Amy J.
Blackburn Robert P.
Chiron Corporation
Harbin Alisa A.
Robins Robert L.
Schwadron Ronald B.
LandOfFree
Conserved motif of hepatitis C virus E2/NS1 region does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conserved motif of hepatitis C virus E2/NS1 region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conserved motif of hepatitis C virus E2/NS1 region will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3313636